Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan

Table 2 Care cascade of incident hepatitis C infections among people living with human immunodeficiency virus in the interferon and direct-acting antiviral eras

	Total 2011-2018, n = 287	Seroconversion in		P value
		2011-2016 IFN era, n = 176	2017-2018DAA era, n = 111
Antibody detected, n (%)1	277 (96.5)	167 (94.9)	110 (99.1)	0.09
HCV RNA tested, n (%)1	270 (97.5)	162 (97.0)	108 (98.2)	0.08
HCV RNA positivity, n (%)1	251 (93.0)	152 (93.8)	99 (91.7)	0.48
Referred to treatment assessment, n (%)1	226 (90.0)	134 (88.2)	92 (92.9)	0.17
Treatment initiated, n (%)1	215 (95.1)	131 (97.8)	84 (91.3)	0.81
SVR achieved, n (%)1	202 (94)	120 (91.6)	82 (97.6)	0.19
Interval between each step, median days (IQR)
Seroconversion to antibody detected	130 (80-295)	179 (87-434)	92 (57-173)	< 0.001
Antibody detected to HCV RNA tested	19 (6-81)	21 (6-93)	12 (6-68)	0.19
HCV RNA tested to treatment assessment	43 (11-181)	26 (7-208)	81 (14-169)	0.25
Treatment assessment to treatment initiation	36 (21-90)	35 (27-90)	42 (18-84)	0.55
Duration of viremia2	502 (325-945)	735 (391-1447)	380 (274-554)	< 0.001
Events of STIs during HCV viremia	220	165	55	< 0.001
Incidence rate of STIs during HCV viremia, (per 100-PYFU)	41.0	38.5	50.5	0.09

¹Percentage that moved from the previous step to current step of care cascade.

²From the time of seroconversion to end of treatment. DAA: Direct-acting antiviral; IFN: Interferon; IQR; Interquartile range; PYFU: Person-years of follow-up; STIs: Sexually transmitted infections; SVR: Sustained virologic response.